

THE IMPACT OF AN INTEGRATED SUPPORTIVE CARE SERVICE FOR PATIENTS WITH INTERSTITIAL LUNG DISEASE



Dr Claire A Douglas^a, Fiona Rowe^b, Dr Sarah Bowers^c, Dr Richard Hammond^b, Dr Andrew Goudie^b

^a Cornhill Macmillan Centre, Perth Royal Infirmary, ^b Respiratory Unit, Ninewells Hospital, ^c Palliative Care, Ninewells Hospital

BACKGROUND

Patients with progressive fibrotic ILD conditions such as idiopathic pulmonary fibrosis (IPF) have a poor prognosis (2-5 yrs) and a high symptom burden, comparable to advanced lung cancer (1).

Studies show that hospital interventions are common at the end of life - 1/3 of patients have end of life decisions made and for 74% this is in the last 3 days of life (2). Death is often 'unexpected' compared to patients with lung cancer (3).

DEVELOPMENT OF THE ILD SUPPORTIVE CARE SERVICE

Funding was secured for one year to develop an integrated service between Respiratory and Palliative Care.

This allowed a specialist ILD nurse (WTE) and a consultant from Palliative Medicine (1 session) to provide a combined clinic with a respiratory consultant with a specialist interest in ILD.

AIMS:

- To improve symptoms by pharmacological and non-pharmacological methods
- To provide holistic care
- To improve ACP discussions and communication

METHODS:

• Fortnightly clinic / MDT with Respiratory & Palliative Care Consultant and Specialist nurse

• Telephone calls / video-consultations / home visits

• Symptom assessment using the palliative Care Outcome Scale (IPOS)




• Breathing – Thinking – Functioning model

• ACP discussions and request to GP to upload to Scottish National Key information Summary (KIS)

Data collected on 50 patients within first 6 months of service

The image shows a portion of the IPOS (Palliative Care Outcome Scale) form, 'IPOS Staff Version'. It includes fields for Patient Name, Patient Number, and Date. The main section is a grid of questions with Likert scales (0-4) for various symptoms such as Pain, Shortness of breath, Fatigue, Nausea, Anxiety, Breathing, Thinking, Functioning, and Drowsiness. There are also questions about the patient's overall health and the impact of their condition.

RESULTS AND CONCLUSIONS



Consultation Type: 32 / 50 patients attended the combined clinic. Home visits, video and telephone consultations were also offered, with some patients receiving all types of consultation, dependent on need.

Symptom Assessment and Control: First and last IPOS scores were available for 33/50 (66%) patients. Symptom burden was high - most symptoms improved; pain (p=0.035) and anxiety (0.040) reduced significantly.

ACP: Pre-service 11/50 (22%) patients had ACP documented on KIS with DNA CPR documented in 4/50 (8%).

Post-consultation, 31/50 (62%) had ACP documented (p=0.003). ACP was uploaded to the KIS in 25/31 (81%). DNACPR discussions were documented for 19/50 (38%) (p=0.008) with 17/19 (89%) of these uploaded to the KIS

Mortality: 11/50 (22%) patients died within the 6 months. Of these, 7/11 (64%) had documented PPD for home. This was achieved in 6/7 (86%).

PATIENT FEEDBACK: "The ILD clinic and dedicated nurse is a first-class initiative. It is supportive, holistic, and proactive. Cannot fault or recommend enough".

CONCLUSION -The integrated ILD Supportive Care service improves symptom burden for patients, supports patients and carers, improves ACP and may reduce unwanted hospital admissions at end of life

References: 1. Carvajalino et al, 2018
2. Rajala et al, 2016
3. Kim, Atkins et al 2019